Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765041 | 0.91 | PPARG (0.44) | GAAKMT2AMEN1PPARGMAPT | |
| SCHEMBL15230373 | 0.87 | GAA (0.39) | GAAKMT2AMEN1MAPTTDP1 | |
| SCHEMBL1765535 | 0.85 | PPARG (0.40) | GAAKMT2AMEN1PPARGALDH1A1 | |
| SCHEMBL15230430 | 0.84 | CCR1 (0.40) | GAAKMT2AMEN1PPARGMAPT | |
| SCHEMBL15230561 | 0.82 | PPARG (0.37) | GAAKMT2AMEN1PPARGMAPT | |
| SCHEMBL15230375 | 0.82 | PPARG (0.35) | GAAKMT2AMEN1PPARGMAPT | |
| SCHEMBL15231208 | 0.81 | PPARG (0.37) | GAAKMT2AMEN1PPARGMAPT | |
| SCHEMBL15231257 | 0.81 | PPARG (0.38) | GAAKMT2AMEN1PPARGMAPT | |
| SCHEMBL15231737 | 0.78 | GAA (0.36) | GAAKMT2AMEN1MAPTTDP1 | |
| SCHEMBL15231212 | 0.78 | GAA (0.36) | GAAKMT2AMEN1PPARGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065481-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| EP-2820011-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013127789-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065481-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | PRF1, CASP1, MPO | GAA 2082/4885KMT2A 4545/4885MEN1 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.